glp-1 news october 1 2025 Pipeline Update: August - Prime Therapeutics Mapping the effectiveness and risks

The once-a-day semaglutide pill is approved for reducing the risk of heart disease and Type 2 diabetes, the company said in a statement Monday.

All of our supplements are manufactured in the USA

High-fiber prepared meals tailored to you to speed results and reduce side effects.

The advanced stage of this is called metabolic dysfunction-associated steatohepatitis, or MASH, which is the leading cause of liver-rated medical conditions and mortality

Roche reported positive Phase II topline data showing that its once-weekly dual glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide receptor agonist CT-388 achieved substantial, sustained, and dose-dependent weight loss through 48 weeks

Understanding the mechanism and management strategies can help you stay comfortable during weight loss treatment